CAR T cells for Malignant Pleural Mesothelioma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Malignant Pleural Mesothelioma+1 MoreCAR T cells - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new targeted cancer treatment in people with a specific type of mesothelioma. The goal is to find the safest dose of the treatment.

Eligible Conditions
  • Malignant Pleural Mesothelioma
  • Mesothelioma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 2 years

2 years
MTD of M28z1XXPD1DNR
overall response rate (ORR)

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Engineered Autologous T Cells
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: CAR T cells · No Placebo Group · Phase 1

Engineered Autologous T CellsExperimental Group · 2 Interventions: cyclophosphamide, CAR T cells · Intervention Types: Drug, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
FDA approved
CAR T cells
2017
Completed Phase 2
~30

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Atara BiotherapeuticsIndustry Sponsor
11 Previous Clinical Trials
673 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,832 Previous Clinical Trials
584,508 Total Patients Enrolled
Roisin O'Cearbhaill, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
18 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: